Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon
Calliditas Therapeutics AB (publ) (“Calliditas”) today…
Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States
Cambridge, UK and New York, US, 24 September 2019. Artios Pharma…
Neuraxpharm provides business update on a transformational year
Neuraxpharm Group (Neuraxpharm), a leading European specialty…
HOX THERAPEUTICS TO PRESENT AT 2019 AACR ANNUAL MEETING
Guildford, UK – 06 February 2019: HOX Therapeutics, the private…
DelSiTech and Innovare Sign Licensing Agreement for the Development of a Long Acting HIV Therapy
Turku, Finland – 18 December 2018: DelSiTech Ltd, a Finnish…
Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product
Receives First Milestone Payment for NXP001
Cambridge, UK,…
INKEF Capital Appoints Roel Bulthuis as Managing Director to Co-Manage Eur 500m Fund
Venture fund focuses on supporting early stage healthcare and…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
